Ligation is a surgical technique in which a ligature is tied around a bodily duct, tube, or blood artery. Protuberant lesions can be successfully treated with endoscopic ligation, which is frequently used to treat bleeding gastric, angiodysplastic, and esophageal varices. It is a viable method for eliminating lesions of the upper gastrointestinal tract. Additionally, it reduces the possibility of associated problems, including perforation and hemorrhage.

The market for ligation devices in 2021 was USD 992.94 million and will reach USD 1745.69 million by 2030 at a 6.47% CAGR during 2021-2030.

Throughout the projection period, market revenue will increase due to the increased prevalence of illnesses such as angiodysplasia, gastric varices, and protuberant gastrointestinal lesions. Future years will likely see a large increase in the number of minimally invasive operations using ligation devices and accessories.

Markey Dynamics

Drivers

The market for ligation devices is growing as a result of an increase in bariatric surgeries, minimally invasive treatments, and cardiovascular and urological problems. A 2017 study by the European Heart Network found that cardiovascular illnesses caused 3.9 million deaths in Europe.

The use of ligation devices will increase as the number of illnesses requiring minimally invasive surgery does. Additionally, encouraging compensation practices, growing healthcare costs, and spending on research and development foster market expansion. These elements will probably increase demand for Ligation Devices. The market will grow as a result of several government initiatives and rising healthcare costs for conditions affecting the digestive system.

Restraints

The cost of ligation devices used in surgical procedures requires a larger investment, which restricts the expansion of the ligation devices market.

The increase of pelvic inflammatory disease and scars from tubal ligations is constraining the market.

Opportunity

The market will develop in the next years as a result of rising healthcare spending, which may be utilized to treat numerous cardiovascular diseases and other conditions. Additionally, a rise in the need for minimally invasive procedures that use ligation devices and related accessories will probably offer a market expansion opportunity in the years to come.

Market Segmentation

• In 2020, the accessories market sector led the entire market with 55% of revenue by Product. Over the forecast period, it is expected to accelerate at a CAGR of 6.9%. This trend can be attributed to an increase in surgical operations, particularly in developing countries. Additionally, this market segment will grow due to its accessibility in various sizes and extensive use in surgical procedures.

• The market for ligation devices was significantly ruled by the “open surgery” segment in 2020. It will expand quickly due to the increase in heart disease cases and open-heart surgeries. Additionally, a number of open-heart surgical procedures, including mitral valve replacement with ligation devices, aortic valve replacement, and coronary artery bypass graft (CABG), are substantially driving the market.

• The gastrointestinal and abdominal surgeries held the largest market share in 2020. Additionally, the cardiovascular surgery sector will expand at a CAGR of 6.9% during the forecasted period. This is due to the increase in cardiovascular disease cases. In addition, as cardiovascular robotic surgery technology develops, the market for ligation devices is anticipated to grow. According to the American College of Cardiology, cardiovascular disease causes 800,000 deaths annually in the United States (2017).

• With more than 75% of the market in 2020, the “hospitals” sector had the biggest market share for ligation devices. Additionally, an increase in procedures, a rise in healthcare expenditure, and an increase in hospitals are the segment’s main drivers. The American Hospital Association (AHA) reports that there were 6,200 operational hospitals in the United States in 2017, up from 5,534 in 2016.

Regional Insights

Due to rising healthcare costs and the prevalence of chronic illnesses, North America held a dominant position in the global market for ligation devices in 2020. The Centers for Disease Control and Prevention reported that coronary heart disease (CHD), which claimed 370,000 lives in 2018, was the most common form of cardiac disease in the United States in 2018. The market expansion is also driven by strong competition and increasing government investment. Thirty million Americans had chronic kidney disease in 2017, according to the National Center for Chronic Disease Prevention and Health Promotion.

Asia Pacific will considerably rule the entire market with a rapid CAGR. The vast patient population and the quick development of infrastructure in the APAC region are the main drivers of the region’s growth. Around 15,000 surgical treatments were carried out in Australia in 2015, according to Monash University, increasing the burden of bariatric surgery.

Key Players 

• Olympus Corporation
• Applied Medical
• Ethicon (Johnson and Johnson)
• ConMed Corporation
• Genicom
• Grena Think Medical
• B.Braun Melsungen AG
• Cooper Surgical
• Teleflex Incorporated
• Medtronic

The market for ligation devices in 2021 was USD 992.94 million and will reach USD 1745.69 million by 2030 at a 6.47% CAGR during 2021-2030. The expansion is driven by an increase in surgical and minimally invasive procedures. The market is also driven by the rise of gynecological, urological, cardiac, and gastrointestinal surgery procedures that call for ligation devices for both diagnostic and therapy.

Live-Cell Imaging is a research project that combines in-vivo monitoring and analysis of live cells. It provides a thorough examination of the biological processes and functions of cells. Researchers and viewers may now view cellular processes at the molecular level thanks to live-cell imaging. Live-cell imaging is a technique for studying live cells by employing images from imaging technologies, including high content screening systems and microscopes.

The market for live cell imaging in 2021 was USD 1.95 billion and will reach USD 4.18 billion by 2030 at an 8.8% CAGR during 2021-2030.

Growing stem cell-based research endeavors and quick technological advancements in a variety of imaging methods used for live-cell observation and analysis are two key factors fostering market revenue growth throughout the forecast period.

Market Dynamics

Drivers

The rise in chronic illness incidence and the desire for rapid diagnostic methods significantly impacts the global demand for live-cell imaging. Additionally, the availability of precise and reliable live-cell imaging methods hastens the development of new drugs and other biotechnology-related studies. The market for live-cell imaging will rise due to an increase in spending and financing for the development of enhanced cell imaging. Major incumbents are increasingly buying small firms to acquire ground-breaking innovations in order to increase their market share.

Restraints

High content screening systems cost more because they include more sophisticated functions. A wide-field microscope can cost more than $100,000, whereas a confocal microscope can cost more than $250,000. Therefore, because these systems are more expensive, it is becoming harder for regular internet users to afford them, which impedes market growth.

The maintenance fees and several other indirect charges, in addition to the high purchase price of these systems, drive up their overall cost.

Opportunity

Due to the expanding R&D activities of numerous firms in countries like Brazil, China, India, and Russia are new participants in the live cell imaging market and provide considerable prospects for live-cell imaging systems. The National Bureau of Statistics said that in 2021, China spent around 2.79 trillion yuan (or $441.13 billion), an increase of 14.2% from the previous year.

Market Segmentation

By product

The equipment segment held a significant market position, with the largest share of nearly 39%. The standalone sub-segment of the equipment segment will rule the overall market. These systems can run independently of any additional hardware. The numerous applications of these systems in live-cell imaging and the growing emphasis on R&D are key factors driving this market segment.

By application

The cell biology segment led the overall market for live cell imaging because of the increasing amount of studies on molecular interaction networks. Aside from this, other cutting-edge technologies that heavily influence the process are the sophisticated illumination systems and filtration approaches.

By technology 

On the basis of technology, the largest market share was held by the fluorescence resonance energy transfer segment owing to its numerous benefits in determining the spatial proximity in the protein levels. Additionally, the increasing use of genetic peptides has recently made this technology more well-known. According to a study published in 2021 titled “Studying SARS-CoV-2 with Fluorescence Microscopy,” it is possible to successfully examine the molecular biology of SARS-CoV-2 and related viruses using a fluorescence microscope. The market will grow as more live cell imaging equipment is used to study the molecular biology of the COVID-19 virus.

Regional Insights

North America held a considerable place in the market, with the largest share in 2020. It is due to the growing senior population and a larger patient pool. The significant funding and commitment made available for live-cell imaging research are the region’s main motivators. The United States has the largest market share in the region of North America because of factors like the rise in chronic illnesses and the number of R&D programs in the country. In the United States, there were approximately 34,800 new HIV infections in 2020, according to the Centers for Disease Control and Prevention. Over 13% of HIV-positive Americans, according to the same source, are unaware of their condition and need a rapid diagnosis.

Key Players 

• Olympus Corporation (Japan)
• PerkinElmer, Inc. (U.S.)
• Danaher Corporation (U.S.)
• Carl Zeiss AG (Germany)
• Nikon Corporation (Japan)
• G.E. Healthcare (U.S.)
• Sartorius AG (Germany)
• Oxford Instruments (U.K.)
• Bruker Corporation (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• BioTek Instruments (US)
• CytoSMART Technologies (Netherlands)
• Etaluma, Inc. (U.S.)
• Deepcell Inc.
• NanoEnTek Inc. (Korea)
• Phase Focus Limited (U.K.)
• Sony Biotechnology, Inc. (U.S.)
• Merck KGaA (Germany)
• KEYENCE Corporation (Japan)
• ibidi GmbH (Germany)
• Bio-Rad Laboratories (U.S.)
• Tomocube, Inc. (South Korea)
• Phase Holographic Imaging PHI AB (Sweden)
• B.D. Biosciences (U.S.
• Logos Biosystems (South Korea)
• Nanolive SA (Switzerland).

The market for live cell imaging in 2021 was USD 1.95 billion and will reach USD 4.18 billion by 2030 at an 8.8% CAGR during 2021-2030. Due to the rising illness burden and rising elderly population around the world, the live cell imaging market is expanding rapidly on a global scale. Additionally, the market will develop as high-content screening approaches are used in drug discovery.